| Trial ID: | L0159 |
| Source ID: | NCT02196831
|
| Associated Drug: |
Tesamorelin
|
| Title: |
Tesamorelin Effects on Liver Fat and Histology in HIV
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT02196831/results
|
| Conditions: |
Human Immunodeficiency Virus (HIV)|Nonalcoholic Fatty Liver Disease (NAFLD)|Nonalcoholic Steatohepatitis (NASH)
|
| Interventions: |
Drug: tesamorelin|Drug: Placebo
|
| Outcome Measures: |
Change in Liver Fat as Measured by 1-H Magnetic Resonance Spectroscopy|Change in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score|Change in Alanine Aminotransferase (ALT)|Change in Aspartate Aminotransferase (AST)
|
| Sponsor/Collaborators: |
Massachusetts General Hospital|National Institute of Allergy and Infectious Diseases (NIAID)
|
| Gender: |
All
|
| Age: |
18 Years to 70 Years ?? (Adult, Older Adult)
|
| Phases: |
Not applicable
|
| Enrollment: |
61
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
July 1, 2015
|
| Completion Date: |
July 24, 2019
|
| Results First Posted: |
January 13, 2020
|
| Last Update Posted: |
January 27, 2020
|
| Locations: |
National Institutes of Health, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT02196831
|
